South Dakota's top prosecutor charged two consultants who worked with a Native American tribe on its plans to open the nation's first marijuana resort with drug offenses, accusing them of having seeds shipped from the Netherlands hidden in CD cases and sewn into clothing.

DAVE JORDANO’S FASCINATION with Detroit’s marijuana dispensaries borders on obsession. He’s photographed more than half of them, and remains fascinated by their bright colors, neon signs, and cheeky names like “House of Dank.”

“I just love this entrepreneurial spirit of all these individuals having their own say in what these shops should look like, what their names are, what strains they sell, what they profess to heal and cure,”Jordano says. “Everyone’s got their own thing going, and it’s very independent.”

The following is a condensed and edited interview with Tripp Keber, CEO, Dixie Brands.
 
Why did you get into the cannabis industry?
I got into the marijuana business, ironically, to make money. Boy, was I wrong in the early days. I realized in a very quick time period that there was far more to this industry than making money. The power of cannabis is just superior to some of the other wellness platforms, so it’s exciting to see us six years later and how the company has grown.
 

Australian investors will soon be able to invest in the latest medical marijuana company set to list on the Australian stock exchange.

Creso Pharma is due to list on the ASX through an initial public offering, with the company seeking to raise $5m upon listing to primarily fund the development of its technologies and products.

The global medical marijuana market is projected to be worth $270 billion, with the Australian market tipped to be valued at $50 billion by 2018.

Security is not only an integral part of any growing legal cannabis business, but it’s also a licensing requirement. Many traditional security companies aren’t open to changing their protocols. I had the chance to talk with Douglas White of Forensic Fog Technologies to discuss how cannabis businesses could change the way everyone looks at security and asset protection – no matter the location.

Jason Sander: Thanks for joining me today, Douglas. Let’s start with your elevator pitch. 

Legalized medical marijuana is coming soon to Ohio, and Marijuana Business Daily is bringing its “crash course” here to inform potential entrepreneurs.

“We chose Ohio because of the potential for the industry,” said Editorial Director Chris Walsh.

Half of the U.S. has legalized marijuana in some form, and the Ohio legislature followed suit this year in response to a ballot push from national advocacy group Marijuana Policy Project. (You can read who donated to the group's Ohio-based campaign here.)

The cannabis industry is starting to see some serious investment activity.

Over the last few years, a new wave of cannabis-finance companies have formed to capitalize on the green rush.

Companies like Tuatara Capital, Seventh Point, Poseidon Asset Management, and Privateer Holdings have dived headfirst into the industry.

While the first three are brand new, having been founded in the last few years, Privateer started in 2011. The fund bills itself as the first in the US to focus solely on cannabis-related endeavors.

The addition of heat to common pesticides can create poison. Organic Maryland LLC has a safe solution that uses no chemical pesticides.

It was a only a matter of weeks after the November 6th deadline to apply for a Maryland medical cannabis grower’s license before the public outcry over Colorado recalls began. In March of this year, the Denver Post reported more than 10 recalls in less than a month. A commonly used pesticide has driven massive recalls in Colorado, prompting concerns over crop safety and product integrity, particularly within the state of Maryland.

After Bernie stepped aside in the race for president of the United States, the closet ally the industry has is Hillary Clinton.

Hillary Clinton is no hero for the marijuana industry, but after the Democratic party endorsed moving marijuana from a Schedule I drug to a Schedule II to allow for more research, 43 percent of cannabis industry executives and professionals said they'd vote for Clinton for president.